Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Intern Med J
; 47 Suppl 4: 5-10, 2017 Jul.
Article
em En
| MEDLINE
| ID: mdl-28685928
ABSTRACT
Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered 'unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Linfocítica Crônica de Células B
/
Clorambucila
/
Anticorpos Monoclonais Humanizados
/
Antineoplásicos Imunológicos
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Intern Med J
Assunto da revista:
MEDICINA INTERNA
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Austrália